Ascorbic Acid Treatment in Charcot-Marie-Tooth Disease Type 1A (CMT1A) Trial

Academic Medical Centre, Department of Neurology (Netherlands)0 个研究点目标入组 12 人开始时间: 2005年11月22日最近更新: 2015年1月13日

试验速览

暂无简介。

•1. DNA-proven CMT1A patients
•2. Age 12-25 years
•3. CMT1A patients with symptomatology defined as muscle weakness in at least foot dorsiflexion

•1. Due to possible influence on severity of the neuropathy:
•1.1. Known other disease that may cause a neuropathy, that may decrease mobility, or that may lead to severe disability or death in a short time
•1.2. Medication that may cause a neuropathy
•1.3. Chronic alcohol abuse
•2. Due to study medication (ascorbic acid):
•2.1. Regular use of vitamin C
•2.2. Clinical or echographic signs of nephrolithiasis
•2.3. Reduced glomerular filtration rate
•2.4. Iron overload
•2.5. No regular dental control at the dentist
•2.6. Pregnancy or active pregnancy wish for women
•3. Due to study design and primary outcome:
•3.1. Not signing the informed consent
•3.2. Psychiatric co-morbidity which may influence compliance
•3.3. Not being comfortable during nerve conduction studies of the median nerve
•3.4. A too small Compound Muscle Action Potential (CMAP) amplitude of the abductor pollicis brevis muscle for a proper determination of the nerve conduction velocity of the median nerve

发起方

Academic Medical Centre, Department of Neurology (Netherlands)